The Distributions of HCV Genotypes in Hemodialysis Patients in Iraq

Hussein, Nawfal; Al-Obeidy, Eman Sh; Naqid, Ibrahim; Abd, Kais H; Abdulrahman, Shakir

doi:10.30699/ijmm.13.4.279

year 13, Issue 4 (September - October 2019) Iran J Med Microbiol 2019, 13(4): 279-283 | Back to browse issues page

‎ 10.30699/ijmm.13.4.279

Mendeley

Zotero

RefWorks

Hussein N, Al-Obeidy E S, Naqid I, Abd K H, Abdulrahman S. The Distributions of HCV Genotypes in Hemodialysis Patients in Iraq. Iran J Med Microbiol 2019; 13 (4) :279-283
URL: http://ijmm.ir/article-1-964-en.html

The Distributions of HCV Genotypes in Hemodialysis Patients in Iraq

Nawfal Hussein¹

, Eman Sh Al-Obeidy²

, Ibrahim Naqid

³, Kais H Abd⁴

, Shakir Abdulrahman¹

1- College of Medicine, University of Zakho, Zakho, Kurdistan region, Iraq
2- Dialysis Center, Baghdad Medical cities, Baghdad, Iraq
3- College of Medicine, University of Zakho, Zakho, Kurdistan region, Iraq , ibrahim.naqid@uoz.edu.krd
4- Duhok Renal Dialysis Center, Duhok, Kurdistan Region, Iraq

Abstract: (3475 Views)

Objectives: The aim of this report was to investigate the genotypes of HCV in patients on regular hemodialysis in Iraq.
Methods: A cross sectional study was conducted to investigate the genotypes of HCV in patients on regular hemodialysis in 7 centers across Iraq. 255 subjects with positive anti-HCV antibodies were recruited in this study.
Results: To confirm the positivity, RTPCR was performed. Amongst all samples, 31% (79/255) was positive by RTPCR. Then, we genotyped all the RTPCR positive samples, it was found that 39/79 (49.4 %) of our samples were typed as HCV genotype 1 including 26 samples (66.7%) as HCV 1a and 13 samples (33.3%) as HCV 1b. HCV genotype 4 was found in 34/79 (43%) of the samples while 6/79 (7.6%) of the samples typed as HCV 3
Conclusions: HCV genotype 1 was the most prevalent genotype followed by genotype 4. Further population-based study is required to investigate the prevalence of HCV genotypes.

Keywords: HCV, Genotypes, Hemodialysis Patients, Iraq

Full-Text [PDF 1070 kb] (1639 Downloads) | | Full-Text (HTML) (1506 Views)

Type of Study: Original Research Article | Subject: Molecular Microbiology
Received: 2019/09/23 | Accepted: 2020/01/19 | ePublished: 2020/01/19

References

1. Flichman DM, Blejer JL, Livellara BI, Re VE, Bartoli S, Bustos JA, et al. Prevalence and trends of markers of hepatitis B virus, hepatitis C virus and human Immunodeficiency virus in Argentine blood donors. BMC infectious diseases. 2014;14(1):218. [DOI:10.1186/1471-2334-14-218] [PMID] [PMCID]

2. Zaheer H, Saeed U, Waheed Y, Karimi S, Waheed U. Prevalence and Trends of Hepatitis B, Hepatitis C and Human Immunodeficiency Viruses among Blood Donors in Islamabad, Pakistan 2005-2013. J Blood Disorders Transf. 2014;5(217):2.

3. Walter SR, Thein H-H, Amin J, Gidding HF, Ward K, Law MG, et al. Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. Journal of hepatology. 2011;54(5):879-86. [DOI:10.1016/j.jhep.2010.08.035] [PMID]

4. Afzal MS, Ahmed T, Zaidi NuSS. Comparison of HCV Prevalence in Pakistan and Iran; An Insight into Future. Hepatitis Monthly. 2014;14(1):e11466. [DOI:10.5812/hepatmon.11466]

5. Kafi-Abad SA, Rezvan H, Abolghasemi H. Trends in prevalence of hepatitis B virus infection among Iranian blood donors, 1998-2007. Transfusion Medicine. 2009;19(4):189-94. [DOI:10.1111/j.1365-3148.2009.00935.x] [PMID]

6. Hussein NR, Haj SM, Almizori LA, Taha AA. The Prevalence of Hepatitis B and C Viruses Among Blood Donors Attending Blood Bank in Duhok, Kurdistan Region, Iraq. International Journal of Infection. 2016;4(1):e39008. [DOI:10.17795/iji-39008]

7. Karkar A. Hepatitis C in dialysis units: The Saudi experience. Hemodialysis International. 2007;11(3):354-67. [DOI:10.1111/j.1542-4758.2007.00192.x] [PMID]

8. Yakaryilmaz F, Alp Gurbuz O, Guliter S, Mert A, Songur Y, Karakan T, et al. Prevalence of Occult Hepatitis B and Hepatitis C Virus Infections in Turkish Hemodialysis Patients. Renal Failure. 2006;28(8):729-35. [DOI:10.1080/08860220600925602] [PMID]

9. Ghorbani NR, Djalalinia S, Modirian M, Abdar ZE, Mansourian M, Gorabi AM, et al. Prevalence of hepatitis C infection in Iranian hemodialysis patients: An updated systematic review and meta-analysis. J Res Med Sci. 2017;22:123-. [DOI:10.4103/jrms.JRMS_223_17] [PMID] [PMCID]

10. Barril G, Traver JA. Decrease in the hepatitis C virus (HCV) prevalence in hemodialysis patients in Spain: effect of time, initiating HCV prevalence studies and adoption of isolation measures. Antiviral Research. 2003;60(2):129-34. [DOI:10.1016/j.antiviral.2003.08.008] [PMID]

11. Gallego E, López A, Pérez J, Llamas F, Lorenzo I, López E, et al. Effect of Isolation Measures on the Incidence and Prevalence of Hepatitis C Virus Infection in Hemodialysis. Nephron Clinical Practice. 2006;104(1):c1-c6. [DOI:10.1159/000093252] [PMID]

12. Ibrahim NM, Saleem ZSM, Hussein NR. The Prevalence of HIV, HCV, and HBV among hemodialysis patients attending Duhok Hemodialysis Center. International Journal of Infection. 2018;5(1). [DOI:10.5812/iji.63246]

13. Te HS, Jensen DM. Epidemiology of Hepatitis B and C Viruses: A Global Overview. Clinics in Liver Disease. 2010;14(1):1-21. [DOI:10.1016/j.cld.2009.11.009] [PMID]

14. Legrand-Abravanel F, Colson P, Leguillou-Guillemette H, Alric L, Ravaux I, Lunel-Fabiani F, et al. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. Journal of Medical Virology. 2009;81(12):2029-35. [DOI:10.1002/jmv.21583] [PMID]

15. Al-Kubaisy W, Al-Naib K, Habib M. Seroprevalence of hepatitis C virus specific antibodies among Iraqi children with thalassaemia. East Mediterr Health J 2006;12(1-2):204-10.

16. Hussein NR, Tunjel I, Basharat Z, Taha A, Irving W. The treatment of HCV in patients with haemoglobinopathy in Kurdistan Region, Iraq: a single centre experience. Epidemiology and Infection. 2016;144(08):1634-40. [DOI:10.1017/S0950268815003064] [PMID]

17. Hussein NR. The efficacy and safety of Sofosbuvir-containing regimen in the treatment of HCV infection in patients with haemoglobinopathy. Mediterranean journal of hematology and infectious diseases. 2017;9(1). [DOI:10.4084/mjhid.2017.005] [PMID] [PMCID]

18. Hussein NR, Saleema ZS, Abd QH. Direct Acting Antiviral Treatment for Patients with End-Stage Kidney Disease with Acute HCV Infection. Mediterranean journal of hematology and infectious diseases. 2019;11(1). [DOI:10.4084/mjhid.2019.034] [PMID] [PMCID]

19. Koshy A, Madda JP, Marcellin P, Martinot M. Treatment of Hepatitis C Virus Genotype 4 Related Cirrhosis: Ribavirin and Interferon Combination Compared With Interferon Alone. Journal of Clinical Gastroenterology. 2002;35(1):82-5. [DOI:10.1097/00004836-200207000-00017] [PMID]

20. Ohno T, Mizokami M, Saleh MG, Orito E, Ohba KI, Wu RR, et al. Usefulness and limitation of phylogenetic analysis for hepatitis C virus core region: application to isolates from Egyptian and Yemeni patients. Archives of Virology. 1996;141(6):1101-13. [DOI:10.1007/BF01718613] [PMID]

21. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev. 2000;13(2):223-35. [DOI:10.1128/CMR.13.2.223] [PMID] [PMCID]